跳转至内容
Merck
CN
  • A chiral separation strategy for acidic drugs in capillary electrochromatography using both chlorinated and nonchlorinated polysaccharide-based selectors.

A chiral separation strategy for acidic drugs in capillary electrochromatography using both chlorinated and nonchlorinated polysaccharide-based selectors.

Electrophoresis (2014-07-02)
Dima Albals, Ans Hendrickx, Lies Clincke, Bezhan Chankvetadze, Yvan Vander Heyden, Debby Mangelings
摘要

A generic chiral separation strategy for the analysis of acidic compounds in CEC is proposed in completion of an earlier defined strategy for nonacidic compounds. The screening step of this strategy uses a 45 mM ammonium formate (pH 2.9)/ACN (35/65, v/v) mobile phase, a temperature of 25°C, and an applied voltage of 15 kV. To update the screening step, eight chiral stationary phases, which all possessed chlorinated and nonchlorinated polysaccharide-based chiral selectors, were evaluated using the earlier defined screening conditions. A combination of the two types of polysaccharide-based chiral phases proved to have the highest cumulative success rate. In the updated screening step, amylose tris(3,5-dimethylphenylcarbamate) (ADH), cellulose tris(4-methylbenzoate) (OJH), cellulose tris(3,5-dichlorophenylcarbamate) (SP5), and cellulose tris(3,5-dimethylphenylcarbamate) (ODRH) were included as selectors and their preferred screening sequence was determined as ADH > OJH > SP5 > ODRH. New optimization steps were also defined for SP5 by investigating the influences of different parameters on the separation outcome using an experimental design approach. After application of the updated strategy, 15 of 17 acidic pharmaceuticals were separated under screening conditions, of which 9 were baseline resolved. When the optimization steps were applied, another three compounds were baseline separated, while the total number of separations was increased by one, which brings the total number of separations to 16 of 17 with 12 baseline separated compounds. This reflects the successful performance of the updated strategy on acidic compounds.

材料
产品编号
品牌
产品描述

Sigma-Aldrich
甲酸, ACS reagent, ≥96%
Sigma-Aldrich
布洛芬, ≥98% (GC)
Supelco
布洛芬, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
硫脲, ACS reagent, ≥99.0%
Sigma-Aldrich
硫脲, ReagentPlus®, ≥99.0%
Sigma-Aldrich
(±)-柚皮素, ≥95%
Sigma-Aldrich
扁桃酸, 99%
USP
布洛芬, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
酮洛芬, ≥98% (TLC)
Sigma-Aldrich
托品酸, 98%
Sigma-Aldrich
甲酸, ≥95%, FCC, FG
Sigma-Aldrich
柚皮素, natural (US), 98%
布洛芬, European Pharmacopoeia (EP) Reference Standard
Supelco
华法林, PESTANAL®, analytical standard
Supelco
酮洛芬, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
布洛芬
Supelco
华法林, analytical standard
Sigma-Aldrich
2-苯基丙酸, 97%
Sigma-Aldrich
2-苯基丁酸, 98%
布洛芬, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
甲酸 溶液, BioUltra, 1.0 M in H2O
USP
华法林, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
布洛芬, meets USP testing specifications
Supelco
氟比洛芬, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
(±)-柚皮素, analytical standard
USP
酮洛芬, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
氟比洛芬, cyclooxygenase inhibitor
Supelco
DL-扁桃酸, analytical standard
Sigma-Aldrich
醋硝香豆素, ≥98% (HPLC)
Sigma-Aldrich
酮洛芬, meets USP testing specifications